Triflusal Triflusal Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux. Triflusal is a selective platelet antiaggregant through; Triflusal is indicated for; In the 2008 guidelines for stroke management from the European Stroke Organization, triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid
Phenylarsonic acid was first prepared by Michaelis and Loenser. X-ray crystallography indicates that the molecules are connected by hydrogen-bonds consistent with short distance of 2.5 Å separating the oxygen atoms. The arsenic center is tetrahedral. Several derivatives of phenylarsonic acid have been used as additives for animal feeds. These include 4-hydroxy-3-nitrobenzenearsonic acid (3-NHPAA, or Roxarsone), "p"-arsanilic acid ("p"-ASA), 4-nitrophenylarsonic acid (4-NPAA), and "p"-ureidophenylarsonic acid ("p"-UPAA). Phenylarsonic acid Phenylarsonic acid is the chemical compound with the formula CHAsO(OH), commonly abbreviated PhAsOH. This colourless solid is an organic derivative of arsenic acid, AsO(OH), where one OH group has been replaced by a phenyl group.